{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:30:08Z","timestamp":1790116208347,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"crossref","award":["16CR2043B"],"award-info":[{"award-number":["16CR2043B"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravitreal methotrexate has been proven to be an effective treatment method for vitreoretinal lymphoma. However, keratopathy occurs as the major side effect during treatment in most cases. The purpose of this study is to describe the characteristics of primary central nervous system lymphoma (PCNSL) with intraocular involvement and to attempt to reduce the incidence of keratopathy caused by intravitreal methotrexate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The medical records of 22 PCNSL patients with intraocular involvement (33 eyes) were reviewed. Patients were divided into two groups. Group A (22 eyes) received the induction-consolidation-maintenance regimen, which consisted of intravitreal methotrexate injection at a dosage of 400\u2009\u03bcg\/0.1\u2009ml twice a week for the first four weeks, weekly for the following eight weeks, and then monthly for the last nine months. Patients with a poor systemic condition were assigned to Group B (8 eyes), who were started on the treatment protocol described above and switched directly to monthly injection (9\u2009months) when ocular remission was achieved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Blurred vision (31%) and floaters (25%) were common presenting symptoms. Vitritis was the most common clinical sign and was present in 29 eyes (90%) on B-ultrasound examination. Diagnosis was made by 25G-pars plana vitrectomy, and most diagnoses were diffuse large B-cell lymphoma. Ocular remission was achieved after 8.2 (SD\u2009=\u20094.6) injections of methotrexate. The mean VA (visual acuity) was improved from LogMAR 0.65 to 0.3 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002). Keratopathy was observed in 21 eyes (66%) after an average of 8.2 (SD\u2009=\u20092.3) injections. With a reduced injection frequency, the incidence of keratopathy was lowered from 86.4% (Group A) to 25.0% (Group B) without ocular recurrence during follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intravitreal methotrexate is a safe, effective and flexible treatment for PCNSL patients with intraocular involvement. Keratopathy is the most common adverse effect and can be controlled by reducing the injection frequency.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-020-01464-3","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T04:04:22Z","timestamp":1589256262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients"],"prefix":"10.1186","volume":"20","author":[{"given":"Xian","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1508-7917","authenticated-orcid":false,"given":"Jianjiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"issue":"5","key":"1464_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.survophthal.2013.12.001","volume":"59","author":"MS Sagoo","year":"2014","unstructured":"Sagoo MS, Mehta H, Swampillai AJ, Cohen VML, Amin SZ, Plowman PN, et al. Primary intraocular lymphoma. Surv Ophthalmol. 2014;59(5):503\u201316.","journal-title":"Surv Ophthalmol"},{"key":"1464_CR2","doi-asserted-by":"crossref","unstructured":"Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008;71(17):1355\u201360. PubMed PMID: 18936428. eng.","DOI":"10.1212\/01.wnl.0000327672.04729.8c"},{"key":"1464_CR3","doi-asserted-by":"crossref","unstructured":"Cho BJ, Kim DY, Park UC, Lee JY, Yoon YH, Yu HG. Clinical features and treatment outcomes of vitreoretinal lymphoma according to its association with CNS lymphoma. Ocul Immunol Inflamm. 2018;26(3):365\u201371. PubMed PMID: 29394118. eng.","DOI":"10.1080\/09273948.2017.1421669"},{"issue":"11","key":"1464_CR4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","volume":"16","author":"CC Chan","year":"2011","unstructured":"Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, et al. Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium. Oncologist. 2011;16(11):1589\u201399.","journal-title":"Oncologist"},{"issue":"3","key":"1464_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/ICU.0000000000000255","volume":"27","author":"D Reichstein","year":"2016","unstructured":"Reichstein D. Primary vitreoretinal lymphoma. Curr Opin Ophthalmol. 2016;27(3):177\u201384.","journal-title":"Curr Opin Ophthalmol"},{"key":"1464_CR6","unstructured":"Tang LJ, Gu CL, Zhang P. Intraocular lymphoma. Int J Ophthalmol. 2017;10(8):1301\u20137. PubMed PMID: 28861359. eng."},{"key":"1464_CR7","doi-asserted-by":"crossref","unstructured":"Kimura K, Usui Y, Goto H. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol. 2012;56(4):383\u20139. PubMed PMID: 22661396. eng.","DOI":"10.1007\/s10384-012-0150-7"},{"key":"1464_CR8","unstructured":"Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med. 2013;15(81):93\u2013100. PubMed PMID: 23449111. eng."},{"issue":"5","key":"1464_CR9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/bjh.14025","volume":"173","author":"F Fend","year":"2016","unstructured":"Fend F, Ferreri AJM, Coupland SE. How we diagnose and treat vitreoretinal lymphoma. Br J Haematol. 2016;173(5):680\u201392.","journal-title":"Br J Haematol"},{"key":"1464_CR10","doi-asserted-by":"crossref","unstructured":"Akpek EK, Ahmed I, Hochberg FH, Soheilian M, Dryja TP, Jakobiec FA, et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology. 1999;106(9):1805\u201310. PubMed PMID: 10485554. eng.","DOI":"10.1016\/S0161-6420(99)90341-X"},{"key":"1464_CR11","doi-asserted-by":"crossref","unstructured":"Merle-Beral H, Davi F, Cassoux N, Baudet S, Colin C, Gourdet T, et al. Biological diagnosis of primary intraocular lymphoma. Br J Haematol. 2004;124(4):469\u201373. PubMed PMID: 14984496. eng.","DOI":"10.1046\/j.1365-2141.2003.04800.x"},{"key":"1464_CR12","doi-asserted-by":"crossref","unstructured":"Raparia K, Chang CC, Chevez-Barrios P. Intraocular lymphoma: diagnostic approach and immunophenotypic findings in vitrectomy specimens. Arch Pathol Lab Med. 2009;133(8):1233\u20137. PubMed PMID: 19653716. eng.","DOI":"10.5858\/133.8.1233"},{"key":"1464_CR13","doi-asserted-by":"crossref","unstructured":"Rajagopal R, Harbour JW. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. Retina. 2011;31(3):435\u201340. PubMed PMID: 21336066. eng.","DOI":"10.1097\/IAE.0b013e31820a6743"},{"issue":"3","key":"1464_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/bjo.2007.127928","volume":"92","author":"S Frenkel","year":"2008","unstructured":"Frenkel S, Hendler K, Siegal T, Shalom E, Pe'Er J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92(3):383\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1464_CR15","doi-asserted-by":"crossref","unstructured":"Riemens A, Bromberg J, Touitou V, Sobolewska B, Missotten T, Baarsma S, et al. Treatment strategies in primary vitreoretinal lymphoma. JAMA Ophthalmol. 2015;133(2):\u2013191.","DOI":"10.1001\/jamaophthalmol.2014.4755"},{"issue":"2","key":"1464_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/eye.2012.250","volume":"27","author":"JL Davis","year":"2013","unstructured":"Davis JL. Intraocular lymphoma: a clinical perspective. Eye. 2013;27(2):153\u201362.","journal-title":"Eye."},{"key":"1464_CR17","doi-asserted-by":"crossref","unstructured":"Abu SK, Oray M, Ebrahimiadib N, Lee S, Anesi S, Foster CS, et al. Ocul Immunol Inflamm. 2016;26(3):347\u201352. PubMed PMID: 27438792. eng.","DOI":"10.1080\/09273948.2016.1193206"},{"key":"1464_CR18","doi-asserted-by":"crossref","unstructured":"Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109(9):1709\u201316. PubMed PMID: 12208721. eng.","DOI":"10.1016\/S0161-6420(02)01125-9"},{"key":"1464_CR19","doi-asserted-by":"crossref","unstructured":"Cassoux N, Merle-Beral H, Leblond V, Bodaghi B, Milea D, Gerber S, et al. Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm. 2000;8(4):243\u201350. PubMed PMID: 11262654. eng.","DOI":"10.1076\/ocii.8.4.243.6463"},{"key":"1464_CR20","doi-asserted-by":"crossref","unstructured":"Kase S, Namba K, Iwata D, Mizuuchi K, Kitaichi N, Tagawa Y, et al. Diagnostic efficacy of cell block method for vitreoretinal lymphoma. Diagn Pathol. 2016;11(1).29.","DOI":"10.1186\/s13000-016-0479-1"},{"issue":"9","key":"1464_CR21","first-page":"1762","volume":"111","author":"RA Zaldivar","year":"2004","unstructured":"Zaldivar RA, Martin DF, Holden JT, Grossniklaus HE. Primary intraocular lymphoma. Ophthalmology. 2004;111(9):1762\u20137.","journal-title":"Ophthalmology."},{"issue":"5","key":"1464_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3109\/09273948.2016.1139733","volume":"25","author":"F Chaput","year":"2017","unstructured":"Chaput F, Amer R, Baglivo E, Touitou V, Kozyreff A, Bron D, et al. Intraocular T-cell lymphoma: clinical presentation, diagnosis, treatment, and outcome. Ocul Immunol Inflamm. 2017;25(5):639\u201348 PubMed PMID: 27002464. eng.","journal-title":"Ocul Immunol Inflamm"},{"key":"1464_CR23","doi-asserted-by":"crossref","unstructured":"Nussenblatt RB, Chan CC, Wilson WH, Hochman J, Gottesman M. International central nervous system and ocular lymphoma workshop: recommendations for the future. Ocul Immunol Inflamm. 2006;14(3):139\u201344.","DOI":"10.1080\/09273940600630170"},{"key":"1464_CR24","doi-asserted-by":"crossref","unstructured":"Levasseur SD, Wittenberg LA, White VA. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes. JAMA Ophthalmol. 2013;131(1):50\u20135. PubMed PMID: 23307208. eng.","DOI":"10.1001\/jamaophthalmol.2013.569"},{"issue":"3","key":"1464_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0161-6420(02)01895-X","volume":"110","author":"A Lobo","year":"2003","unstructured":"Lobo A, Lightman S. Vitreous aspiration needle tap in the diagnosis of intraocular inflammation. Ophthalmology. 2003;110(3):595\u20139.","journal-title":"Ophthalmology."},{"key":"1464_CR26","doi-asserted-by":"crossref","unstructured":"Pe'Er J, Hochberg FH, Foster CS. Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm. 2009;17(5):299\u2013306. PubMed PMID: 19831557. eng.","DOI":"10.3109\/09273940903370755"},{"issue":"12","key":"1464_CR27","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kjms.2016.07.010","volume":"32","author":"Y-C Huang","year":"2016","unstructured":"Huang Y-C, Jou J-R. Intravitreal injections of methotrexate in treatment of primary central nervous system lymphoma with intraocular involvement. Kaohsiung J Med Sci. 2016;32(12):638\u20139.","journal-title":"Kaohsiung J Med Sci"},{"issue":"2","key":"1464_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1365-2141.2004.05028.x","volume":"126","author":"A Hormigo","year":"2004","unstructured":"Hormigo A, Abrey L, Heinemann M-H, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol. 2004;126(2):202\u20138.","journal-title":"Br J Haematol"},{"key":"1464_CR29","doi-asserted-by":"crossref","unstructured":"Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Ruda R, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16(7):e322\u201332. PubMed PMID: 26149884. eng.","DOI":"10.1016\/S1470-2045(15)00076-5"},{"issue":"3","key":"1464_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11060-014-1581-4","volume":"120","author":"B-J Cho","year":"2014","unstructured":"Cho B-J, Yu HG. Risk factors for intraocular involvement in patients with primary central nervous system lymphoma. J Neuro-Oncol. 2014;120(3):523\u20139.","journal-title":"J Neuro-Oncol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01464-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-020-01464-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01464-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T19:36:26Z","timestamp":1620761786000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01464-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1464"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01464-3","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"19 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the guidelines of the Declaration of Helsinki and was granted approval by the Ethics Committee of Huashan Hospital, Fudan University. Written consent was acquired from every patient included in this research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of identifying patient\/clinical data and identifiable images was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}